6
Oct
2026

Chunghwa Chemical Synthesis & Biotech Co

Exhibitor at CPHI Milan 2026 stand 2C114, API
About Us

Chunghwa Chemical Synthesis & Biotech Co. Ltd. (CCSB), founded in 1964, is one of the largest API manufacturers in Taiwan. CCSB is a FDA /EU approved cGMP API plant to produce synthesis and biotechnology products. CCSB has filed US DMF, EDMF and COS for several products. Our products include Mycophenolate Mofetil, Rapamycin (Sirolimus), Tacrolimus Monohydrate, Everolimus, Caspofungin Acetate , etc. CCSB also offers contract manufacturing in the cGMP plants. Currently, CCSB is making APIs for European clients under contract and supplying intermediates to new drug companies.

  • Country/Region:
    Taiwan
  • On CPHI since:
    2015
  • Employees:
    250 - 499
Company types
CMO/CDMO
Pharmaceutical company
Contact info
Event information
CPHI Milan 2026
  • 6 Oct 2026 - 8 Oct 2026
  • Fiera Milano, Italy
  • Visit us at stand 2C114, API

Products Featured at CPHI Milan 2026

  • Eevrolimus

    Product Eevrolimus

    Anticancer/Immunosuppressant
  • Everolimus

    Product Everolimus

    Chunghwa chem synthesis & biotech co. offers a wide range of api products which includes everolimus. It belongs to immunosuppressant and oncology category. Contact us for more information.
  • Semaglutide

    Product Semaglutide

    CCSB commercialized fermentation and semi-synthesis products like Tacrolimus, Everolimus, Sirolimus and Caspofungin Acetate and are in position to offer the these expertises to Semaglutide API. 
  • Tacrolimus

    Product Tacrolimus

    Chunghwa chem synthesis & biotech co. offers a wide range of api products which includes tacrolimus. It belongs to immunosuppressant category. Contact us for more information.
  • Caspofungin Acetate

    Product Caspofungin Acetate

    Chunghwa chem synthesis & biotech co. offers a wide range of api products which includes caspofungin acetate. It belongs to antifungal category. Contact us for more information.